<DOC>
	<DOC>NCT00577395</DOC>
	<brief_summary>The purpose of this trial is to compare the difference in bone microarchitecture of the distal radius at month 12 in postmenopausal osteopenic women treated with risedronate 150mg taken once a month compared to placebo.</brief_summary>
	<brief_title>Bone Microarchitecture in Osteopenic Postmenopausal Women</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Risedronate Sodium</mesh_term>
	<mesh_term>Etidronic Acid</mesh_term>
	<criteria>Female: 40 and 57 years of age inclusive cessation of menstruation (surgical or natural) between 12 and 36 months prior to study enrollment have osteopenia defines as having the following: have osteopenia defined as having the following: Lumbar spine (L1L4) Bone Mineral Density (BMD) T score 1 and less than 2.5 AND a total hip T score of greater than 2.5 OR Lumbar spine (L1L4) BMD T score greater than 2.5 AND a total hip T score 1 and less than 2.5; have a body mass index (BMI) between 18 and 30 kg/m2. history of uncontrolled hyperparathyroidism, hyperthyroidism, osteomalacia use of medications within 3 months of starting study drug that impact bone metabolism such as glucocorticoids, estrogens, calcitonin, calcitriol, other bisphosphonates and parathyroid hormone hypocalcemia or hypercalcemia of any cause</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>57 Years</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>